Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib

Published:2021-05-06 Issue:12 Volume:10 Page:3896-3904
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Qin Boyu¹,Xin Lingli²,Hou Qingxiang²,Yang Bo¹,Zhang Jing¹,Qi Xiaoguang¹,Wei Yingtian³,Hu Yi¹,Xiong Qi¹^ORCID

Affiliation:

1. Department of Oncology General Hospital of Chinese PLA Beijing China

2. Department of Gynaecology and Obstetrics PLA Rocket Force Characteristic Medical Center Beijing China

3. Department of Radiology The First Medical Center of Chinese PLA General Hospital Beijing China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3941

Reference27 articles.

1. Cellular and molecular biology of small cell lung cancer: an overview;Karachaliou N;Transl Lung Cancer Res,2016

2. Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)

3. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

4. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

5. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic effect of additional anlotinib and immunotherapy as second‐line or later‐line treatment in pancreatic cancer: A retrospective cohort study;Cancer Innovation;2024-05-14

2. Inflammation‐based prognostic scoring system for predicting the prognosis of advanced small cell lung cancer patients receiving anlotinib monotherapy;Journal of Clinical Laboratory Analysis;2022-11-28

3. The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis;Tumori Journal;2022-05-04

4. Efficacy and Safety of Drug-Eluting Bead Bronchial Arterial Chemoembolization Plus Anlotinib in Patients With Advanced Non-small-Cell Lung Cancer;Frontiers in Cell and Developmental Biology;2021-10-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3